Thomas Beck MD

Thomas Beck MD General Information

Biography

Dr. Thomas Beck served as Chief Medical Officer and Board Member at Promentis Pharmaceuticals. He also served as Executive Partner at F-Prime Capital Partners. He served as a Board member at Xilio Therapeutics. He joined F-Prime as an Executive Partner in September 2007. Most recently he served as President, Chief Operating Officer at Dyax Corp. Before that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc. (Chairman and Chief Executive Officer), and Enzytech, Inc. (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development. Dr. Beck is Board-certified in Internal Medicine and Nephrology and was an Assistant Professor of Medicine at Temple University School of Medicine before joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University. Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., Symbiomix Therapeutics, and Akriveia Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics and currently is Head, Research and Development at Symbiomix.